Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964853 | 0.97 | LMNA (0.54) | LMNASMN1; SMN2HPGDCHRM4STAT3 | |
| SCHEMBL14965182 | 0.85 | ADRB2 (0.47) | KMT2A | |
| SCHEMBL16293865 | 0.84 | LMNA (0.55) | LMNASMN1; SMN2HPGDCHRM4STAT3 | |
| SCHEMBL14965610 | 0.81 | ADRB2 (0.40) | — | |
| SCHEMBL16293295 | 0.79 | POLB (0.58) | KMT2A | |
| SCHEMBL14965500 | 0.79 | POLB (0.58) | KMT2A | |
| SCHEMBL14965505 | 0.77 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2HPGDCHRM4STAT3 | |
| SCHEMBL16294075 | 0.76 | POLB (0.55) | KMT2A | |
| SCHEMBL14965564 | 0.76 | LMNA (0.61) | LMNASMN1; SMN2HPGDCHRM4STAT3 | |
| SCHEMBL28813755 | 0.75 | LMNA (0.69) | LMNASMN1; SMN2HPGDCHRM4STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | LMNA 3153/4885SMN1; SMN2 3639/4885HPGD 2232/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | LMNA 3254/4885SMN1; SMN2 3669/4885HPGD 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.